Cancers, Volume 11, Issue 10
2019 October - 215 articles
Cover Story: Despite advancements in therapy, the development of castrate resistance in prostate cancer (PCa) remains a major clinical hurdle. An emerging and increasingly appreciated impediment in the treatment of advanced PCa is the development of neuroendocrine differentiation (NED), also known as treatment-induced neuroendocrine prostate cancer (t-NEPC) that is aggressive and lacks therapeutic approaches. It is believed that androgen deprivation therapy may be a predominant mediator in the development of the t-NEPC phenotype. Intriguingly, although classical NEPC is rare in the clinic, it is estimated that ~30% of PCa patients develop t-NEPC. It is therefore crucial to identify the molecular and cellular mechanisms, including the role of tumor microenvironment (TME) that orchestrates t-NEPC, with the goal of developing novel and specific treatment modalities against this aggressive form of the disease. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
